LGALS9 and pancreatic neoplasm: Given the importance of galectin-9 in anti-PD1 resistance and its role in pancreatic carcinogenesis, tolerogenic reprogramming and adaptive immune suppression targeting galectin-9 and PD-1 may be a promising strategy to unblock the immune response in pancreatic cancer.